Create Medicines (formerly Myeloid Therapeutics) announced a rebrand and an expanded development strategy to program multiple immune cell lineages in vivo using its mRNA‑LNP platform. The company said it will broaden efforts beyond myeloid cells to include T cells and NK cells, pursuing in vivo CAR approaches against solid‑tumor antigens such as HER2, TROP2 and GPC3. CEO Daniel Getts framed the move as leveraging prior myeloid programming data to deliver scalable, redosable off‑the‑shelf immunotherapies without complex ex‑vivo manufacture. Create plans multilineage in vivo CARs to enhance tumor control and reduce preconditioning needs. The strategic shift underscores growing industry focus on in‑body cell programming as a route to simplify cell‑therapy logistics and lower costs compared with ex‑vivo CAR manufacturing.